As of 2026-09-22, the EV/EBITDA ratio of Altimmune Inc (ALT) is -6.05. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Altimmune's latest enterprise value is 607.65 mil USD. Altimmune's TTM EBITDA according to its financial statements is -100.42 mil USD. Dividing these 2 quantities gives us the above Altimmune EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.3x - 16.3x | 15.5x |
| Forward P/E multiples | 18.5x - 20.8x | 19.2x |
| Fair Price | (9.40) - (8.27) | (8.81) |
| Upside | -387.4% - -352.9% | -369.5% |
| Date | EV/EBITDA |
| 2026-09-18 | -6.01 |
| 2026-09-17 | -5.99 |
| 2026-09-16 | -5.99 |
| 2026-09-15 | -5.97 |
| 2026-09-14 | -6.11 |
| 2026-09-11 | -6.05 |
| 2026-09-10 | -6.09 |
| 2026-09-09 | -6.21 |
| 2026-09-08 | -6.23 |
| 2026-09-04 | -6.34 |
| 2026-09-03 | -5.97 |
| 2026-09-02 | -6.07 |
| 2026-09-01 | -5.70 |
| 2026-08-31 | -5.74 |
| 2026-08-28 | -5.74 |
| 2026-08-27 | -5.99 |
| 2026-08-26 | -5.82 |
| 2026-08-25 | -5.92 |
| 2026-08-24 | -5.74 |
| 2026-08-21 | -5.74 |
| 2026-08-20 | -5.43 |
| 2026-08-19 | -5.76 |
| 2026-08-18 | -5.47 |
| 2026-08-17 | -5.53 |
| 2026-08-14 | -5.41 |
| 2026-08-13 | -5.30 |
| 2026-08-12 | -5.39 |
| 2026-08-11 | -5.53 |
| 2026-08-10 | -5.63 |
| 2026-08-07 | -5.68 |
| 2026-08-06 | -5.55 |
| 2026-08-05 | -5.59 |
| 2026-08-04 | -5.66 |
| 2026-08-03 | -5.53 |
| 2026-07-31 | -5.22 |
| 2026-07-30 | -5.49 |
| 2026-07-29 | -5.37 |
| 2026-07-28 | -5.51 |
| 2026-07-27 | -5.45 |
| 2026-07-24 | -5.08 |
| 2026-07-23 | -5.22 |
| 2026-07-22 | -5.16 |
| 2026-07-21 | -5.18 |
| 2026-07-20 | -5.16 |
| 2026-07-17 | -5.28 |
| 2026-07-16 | -5.24 |
| 2026-07-15 | -5.49 |
| 2026-07-14 | -5.39 |
| 2026-07-13 | -5.51 |
| 2026-07-10 | -5.63 |